Business Analyst
Arrowhead Pharmaceuticals
Business Analyst
Arrowhead Pharmaceuticals
Develops RNAi-based gene-silencing therapies
Arrowhead Pharmaceuticals, Inc. (Nasdaq ARWR) is a commercial stage biopharmaceutical company that develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The depth and versatility of our RNAi technologies enables us to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologics. Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver and lung with a promising pipeline of preclinical candidates.
Arrowhead’s corporate headquarters is in Pasadena, CA with research and development teams in Madison, WI & San Diego, CA, and a state of the art manufacturing facility in Verona, WI. Our employees are nimble, science-driven innovators who are collaborating to bring new therapies to patients in need.
The Position
We are seeking a Business and Data Analyst, Corporate Functions, to join our Enterprise Systems team, with primary accountability for the administration, optimization, and governance of the enterprise platforms that support our Legal and People Services & Culture partners. This role serves as the functional administrator of our Agiloft Contract Lifecycle Management (CLM) system and as the day-to-day systems partner to People Services & Culture, ensuring these platforms remain scalable, operationally efficient, and compliant with internal controls and regulatory requirements.
Beyond functional administration, this role plays a key part in working closely with Ex. Director of AI and Data Enterprise Management to support data integration across all business partners. Working with Legal, People Services & Culture, and other corporate and business functions, the analyst will identify priority data sources, define data models and reporting needs, and provide trusted, governed datasets and reporting that enable enterprise-wide analytics and business intelligence (BI).
The ideal candidate brings hands-on experience administering enterprise business applications (ideally a CLM platform), a strong command of data modeling, BI analytics, AI data tools, and demonstrated proficiency with the Microsoft Power Platform, Microsoft Fabric and other data platforms to drive automation and actionable insight delivery.
This is an individual contributor (IC) role reporting into the Enterprise Systems team. The position requires close collaboration with business end-users, internal Information Systems (IS) colleagues, and third-party consulting partners to deliver sustainable, high-impact solutions aligned with organizational objectives.
This role is based onsite 5 days a week from one of Arrowhead's office locations.
Responsibilities
Requirements
Preferred
Arrowhead provides competitive salaries and an excellent benefit package.
Candidates must have current, valid authorization to work in the country where this role is located.
Wisconsin pay range 60000 - 68000 USD
California pay range 68000 - 75000 USD
Develops RNAi-based gene-silencing therapies
Arrowhead Pharmaceuticals develops medicines using RNA interference (RNAi) to silence disease-causing genes. The company’s approach uses a library of RNA chemistries and delivery methods to trigger RNAi, enabling rapid and durable reduction of target gene expression in cells. This gene-silencing strategy aims to treat severe genetic diseases such as cystic fibrosis and hepatitis B by lowering disease-related proteins. Arrowhead’s products are advanced through discovery and development partnerships, licensing deals, and potential commercialization of approved therapies. The company differentiates itself through a broad RNAi platform, proprietary delivery tech, and collaborations with larger pharma firms to advance its pipeline. Its goal is to provide new treatment options for conditions with limited or no effective therapies by translating gene silencing into medicines that can halt or reverse disease progression.
Explore more opportunities at Arrowhead Pharmaceuticals